In the absence of consistent evidence of safe and effective pharmacotherapies for stimulant use disorder, psychosocial interventions are the mainstay of treatment. Contingency management is most supported by the evidence but only provides marginal benefits compared to currently provided TAU and is not widely available. People experience many barriers to accessing currently available treatments so these barriers should be addressed to improve treatment for people with stimulant use disorder.